Vascular Biogenics Ltd (NASDAQ:VBLT) was the target of a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 308,500 shares, a decline of 20.7% from the August 15th total of 389,100 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average daily trading volume, of 353,500 shares, the short-interest ratio is currently 0.9 days.
Several equities analysts have recently issued reports on VBLT shares. Zacks Investment Research upgraded Vascular Biogenics from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research report on Friday, August 21st. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of Vascular Biogenics in a research report on Tuesday, June 23rd. Roth Capital reiterated a “buy” rating and set a $5.00 price objective on shares of Vascular Biogenics in a research report on Wednesday, May 27th. Finally, Chardan Capital restated a “buy” rating and issued a $5.00 target price on shares of Vascular Biogenics in a research report on Thursday, August 13th. Six investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $3.40.
NASDAQ:VBLT opened at $1.40 on Wednesday. Vascular Biogenics has a 12-month low of $0.90 and a 12-month high of $1.64. The company has a quick ratio of 6.41, a current ratio of 6.41 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $58.70 million, a PE ratio of -2.37 and a beta of 0.75. The firm has a 50-day moving average price of $1.27 and a 200 day moving average price of $1.27.
Vascular Biogenics (NASDAQ:VBLT) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.14). The firm had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.19 million. Vascular Biogenics had a negative net margin of 2,987.11% and a negative return on equity of 57.70%. On average, research analysts expect that Vascular Biogenics will post -0.56 EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of VBLT. Advisor Group Holdings Inc. acquired a new stake in shares of Vascular Biogenics during the first quarter worth approximately $69,000. Envestnet Asset Management Inc. acquired a new stake in shares of Vascular Biogenics during the first quarter worth approximately $48,000. Wedbush Securities Inc. acquired a new stake in shares of Vascular Biogenics during the second quarter worth approximately $29,000. Phoenix Holdings Ltd. acquired a new stake in shares of Vascular Biogenics during the second quarter worth approximately $27,000. Finally, Virtu Financial LLC acquired a new stake in shares of Vascular Biogenics during the second quarter worth approximately $25,000. 6.10% of the stock is owned by institutional investors.
About Vascular Biogenics
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Featured Article: What is a Futures Contract?
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.